Status
Conditions
Treatments
About
The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be followed for at least 2 years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants must have at least one of the following symptoms/signs or history
Exclusion criteria
500 participants in 2 patient groups
There are currently no registered sites for this trial.
Central trial contact
Sung-Chun Tang, MD, PhD; Chih-Hao Chen, MD, PhD
Start date
Jan 01, 2019 • 6 years ago
Today
Jan 22, 2025
End date
Dec 31, 2026 • in 1 year and 11 months
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal